Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abraxane and Radiation for Stage III NSCLC
NCT00903942Phase 2Withdrawn
- Sponsor
- University of Rochester
- Start
- Mar 2008
- Primary completion
- Mar 2012
- Modality
- Polymer-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nab-paclitaxel in non-small cell lung cancer (NSCLC), sponsored by University of Rochester. Primary endpoint: Feasibility of regimen at 4 years. Planned start Mar 2008; status: withdrawn.
02
Drugs
nab-paclitaxel
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00903942.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00903942.